TW363969B - Galanthamine derivatives and their use as medicaments - Google Patents
Galanthamine derivatives and their use as medicamentsInfo
- Publication number
- TW363969B TW363969B TW083109526A TW83109526A TW363969B TW 363969 B TW363969 B TW 363969B TW 083109526 A TW083109526 A TW 083109526A TW 83109526 A TW83109526 A TW 83109526A TW 363969 B TW363969 B TW 363969B
- Authority
- TW
- Taiwan
- Prior art keywords
- hydrogen
- carbonyloxy
- medicaments
- halo
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/137,440 US6323195B1 (en) | 1993-10-15 | 1993-10-15 | Galanthamine derivatives as acetylcholinesterase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
TW363969B true TW363969B (en) | 1999-07-11 |
Family
ID=22477446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW083109526A TW363969B (en) | 1993-10-15 | 1994-10-14 | Galanthamine derivatives and their use as medicaments |
Country Status (23)
Country | Link |
---|---|
US (2) | US6323195B1 (zh) |
EP (2) | EP1020470A3 (zh) |
JP (1) | JP2664344B2 (zh) |
KR (1) | KR0169114B1 (zh) |
CN (1) | CN1039911C (zh) |
AT (1) | ATE212348T1 (zh) |
AU (1) | AU696249B2 (zh) |
CA (1) | CA2118174C (zh) |
CZ (1) | CZ287071B6 (zh) |
DE (1) | DE69429708T2 (zh) |
DK (1) | DK0653427T3 (zh) |
EG (1) | EG20472A (zh) |
ES (1) | ES2171428T3 (zh) |
FI (1) | FI108723B (zh) |
IL (1) | IL111274A (zh) |
NO (1) | NO310415B1 (zh) |
NZ (1) | NZ264683A (zh) |
PL (1) | PL177730B1 (zh) |
PT (1) | PT653427E (zh) |
RO (1) | RO114133B1 (zh) |
RU (1) | RU2114850C1 (zh) |
TW (1) | TW363969B (zh) |
ZA (1) | ZA948062B (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9514821D0 (en) * | 1995-07-19 | 1995-09-20 | Sod Conseils Rech Applic | Galanthamine derivatives |
AT403803B (de) | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
EP1133230A4 (en) * | 1998-11-23 | 2004-05-26 | Bonnie M Davis | DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS |
SK287676B6 (sk) | 1998-12-24 | 2011-05-06 | Janssen Pharmaceutica N. V. | Prostriedok s riadeným uvoľňovaním obsahujúci galantamín, spôsob jeho prípravy, dávková forma a farmaceutické balenie s jeho obsahom a použitie galantamínu na výrobu tohto prostriedku |
EP1150695B1 (en) * | 1999-01-11 | 2007-02-28 | Atanas Russinov Djananov | Herbal supplement for increased muscle strength and endurance for athletes |
US8603546B2 (en) * | 1999-01-11 | 2013-12-10 | Herbaceuticals Inc. | Herbal supplement for increased muscle strength and endurance for athletes |
ES2211056T3 (es) * | 1999-03-31 | 2004-07-01 | Eisai Co., Ltd. | Composiciones estabilizadas que contienen farmacos nootropicos. |
ES2250211T3 (es) * | 1999-10-26 | 2006-04-16 | Janssen Pharmaceutica N.V. | Disolucion oral que contiene galantamina y un agente edulcorante. |
WO2001043697A2 (en) * | 1999-12-10 | 2001-06-21 | Bonnie Davis | Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
DE50101827D1 (de) | 2000-03-31 | 2004-05-06 | Sanochemia Pharmazeutika Ag Wi | Neue derivate und analoga von galanthamin |
US20030162770A1 (en) * | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
WO2005065661A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galanthamine |
CA2552114A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
EP1779867A4 (en) * | 2004-07-01 | 2009-12-02 | Eisai R&D Man Co Ltd | MEANS FOR PROMOTING NERVE REVENERATION |
PL1895994T3 (pl) * | 2005-05-13 | 2011-02-28 | Alza Corp | Wielowarstwowy system podawania leków z barierą zabezpieczającą przed wypływaniem materiału ze zbiornika |
US20080188510A1 (en) * | 2005-05-23 | 2008-08-07 | Eisai R & D Management Co., Ltd. | Novel methods using zonisamide |
EP1777222A1 (en) * | 2005-09-22 | 2007-04-25 | Galantos Pharma GmbH | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
ATE473219T1 (de) * | 2005-09-22 | 2010-07-15 | Galantos Pharma Gmbh | Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen |
US20090253654A1 (en) | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US20070104771A1 (en) * | 2005-09-23 | 2007-05-10 | Jay Audett | Transdermal galantamine delivery system |
WO2009127218A1 (en) | 2008-04-14 | 2009-10-22 | Galantos Pharma Gmbh | Derivatives of galantamine as pro-drugs for the treatment of human brain diseases |
US20120184532A1 (en) * | 2009-07-23 | 2012-07-19 | Shire Llc | Galantamine amino acid and peptide prodrugs and uses thereof |
WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
EP3628315A1 (en) | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases |
CN113292420A (zh) * | 2021-05-27 | 2021-08-24 | 神隆医药(常熟)有限公司 | 加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL122665B1 (en) | 1978-11-21 | 1982-08-31 | Edinen Zentar Chim | Process for preparing novel dienones of narvedine type and their derivatives |
US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
US6150354A (en) * | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
EP0363415B1 (en) * | 1987-05-04 | 2008-10-15 | Davis, Bonnie | Compounds for the treatment of alzheimer's disease |
NL8800350A (nl) | 1988-02-12 | 1989-09-01 | Stichting Biomedical Research | Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen. |
WO1992020327A1 (en) | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
US5153193A (en) | 1991-10-01 | 1992-10-06 | Hoechst-Roussel Pharmaceuticals Incorporated | Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs |
US5231093A (en) * | 1991-10-01 | 1993-07-27 | Hoechst-Roussel Pharmaceuticals Incorporated | Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs |
-
1993
- 1993-10-15 US US08/137,440 patent/US6323195B1/en not_active Expired - Lifetime
-
1994
- 1994-10-10 EP EP00107570A patent/EP1020470A3/en not_active Withdrawn
- 1994-10-10 DK DK94115959T patent/DK0653427T3/da active
- 1994-10-10 ES ES94115959T patent/ES2171428T3/es not_active Expired - Lifetime
- 1994-10-10 DE DE69429708T patent/DE69429708T2/de not_active Expired - Lifetime
- 1994-10-10 EP EP94115959A patent/EP0653427B1/en not_active Expired - Lifetime
- 1994-10-10 PT PT94115959T patent/PT653427E/pt unknown
- 1994-10-10 AT AT94115959T patent/ATE212348T1/de active
- 1994-10-13 FI FI944821A patent/FI108723B/fi not_active IP Right Cessation
- 1994-10-13 IL IL11127494A patent/IL111274A/xx not_active IP Right Cessation
- 1994-10-13 EG EG64194A patent/EG20472A/xx active
- 1994-10-13 NZ NZ264683A patent/NZ264683A/en not_active IP Right Cessation
- 1994-10-13 RU RU94036448A patent/RU2114850C1/ru active
- 1994-10-14 ZA ZA948062A patent/ZA948062B/xx unknown
- 1994-10-14 RO RO94-01669A patent/RO114133B1/ro unknown
- 1994-10-14 TW TW083109526A patent/TW363969B/zh not_active IP Right Cessation
- 1994-10-14 PL PL94305456A patent/PL177730B1/pl unknown
- 1994-10-14 AU AU75814/94A patent/AU696249B2/en not_active Expired
- 1994-10-14 KR KR1019940026303A patent/KR0169114B1/ko active IP Right Grant
- 1994-10-14 NO NO19943893A patent/NO310415B1/no not_active IP Right Cessation
- 1994-10-14 CN CN94117060A patent/CN1039911C/zh not_active Expired - Lifetime
- 1994-10-14 CZ CZ19942546A patent/CZ287071B6/cs not_active IP Right Cessation
- 1994-10-14 CA CA002118174A patent/CA2118174C/en not_active Expired - Lifetime
- 1994-10-17 JP JP6250778A patent/JP2664344B2/ja not_active Expired - Fee Related
-
1995
- 1995-05-22 US US08/445,921 patent/US5777108A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW363969B (en) | Galanthamine derivatives and their use as medicaments | |
AU3677393A (en) | 2-Oxoethyl derivatives as immunosuppressants | |
AU676884B2 (en) | 1H-indole-3-acetamide sPLA2 inhibitors | |
AU7077894A (en) | Immunosuppressant and antiallergic compounds, e.g. n-(3-oxohexanoyl) homoserine lactone | |
EP1288199A4 (en) | INHIBITORS OF MMP-12 | |
TW347387B (en) | Piperidine derivatives | |
ATE183182T1 (de) | S-triazinderivate als lichtschutzmittel | |
MY110191A (en) | 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | |
MY131501A (en) | Process for the prepration of clavulanic acid | |
GR3017243T3 (en) | Antiemetic and migraine suppressing heterocyclic compounds and pharmaceutical compositions containing them. | |
AU7581294A (en) | Galanthamine derivatives, a process for their preparation and their use as medicaments | |
AU4616893A (en) | New benzopyran compounds, process for their preparation and the pharmaceutical compositions which contain them | |
MY117092A (en) | Chemotherapeutic pyrrolocarbazole derivatives | |
AU7589494A (en) | Pyrrolidine derivatives | |
GB9015485D0 (en) | Heterocyclic derivatives | |
TW218379B (en) | Hydroxymethylpolythiophene derivative | |
CA2117330A1 (en) | The use of psoralen compounds to inhibit restenosis following angioplasty |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |